ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Final Results of the Phase II RE-ExPEL Study: Ramucirumab Beyond Progression + TAS 102 in Advanced/Metastatic Adenocarcinoma of the Stomach or GEJ, After Treatment Failure on a Ramucirumab-Based Therapy
By
ASCO GI 2023 Conference Coverage
FEATURING
Thorsten Oliver Götze
By
ASCO GI 2023 Conference Coverage
FEATURING
Thorsten Oliver Götze
171 views
January 31, 2023
Comments 0
Login to view comments.
Click here to Login
Videos